We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Reaction Vessel Heating System Is Cleaner and Safer

By LabMedica International staff writers
Posted on 20 Aug 2014
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).
Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new high performance reaction block that can be used with any hotplate stirrer.

The Asynt (Isleham, United Kingdom) DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block accommodating three round-bottomed flasks (10 to 500 milliliters) or up to 12 reaction tubes or vials.

DrySyn MULTI heating blocks, which are made of chemically resistant, anodized aluminum, offer excellent heating performance to over 300 degrees Celsius. They are able to heat a reaction flask faster than an oil bath with less energy consumption and without the inherent risks and mess of an oil bath.

The DrySyn MULT system is based on an ingenious three-way clamp that secures flasks in place. Furthermore, DrySyn MULTI's shallow well shape increases reaction visibility and minimizes the possibility of glass failure.

Related Links:

Asynt


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
POC Immunoassay Analyzer
Procise DX

Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
PURITAN MEDICAL